Non–Small Cell Lung Cancer, Version 6.2015

Ettinger, David S., Wood, Douglas E., Akerley, Wallace, Bazhenova, Lyudmila A., Borghaei, Hossein, Camidge, David Ross, Cheney, Richard T., Chirieac, Lucian R. +29 more·2015·Journal of the National Comprehensive Cancer Network
DOI 10.6004/jnccn.2015.0071

Cited by (479)

Items 101–200 of 479

  1. Outcomes of Curative‐Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma
    Kun Woo Kim, Hong Kwan Kim, Jhingook Kim, Young Mog Shim, Myung‐Ju Ahn, Yoon‐La Choi · 2017 · World Journal of Surgery
  2. Real‐world EGFR testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
    Ying Cheng, Yan Wang, Jun Zhao, Yunpeng Liu, Hongjun Gao, Kewei Ma, Shucai Zhang, Hua Xin, Jiwei Liu, Cheng‐Bo Han et al. · 2018 · Thoracic Cancer
  3. Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer
    Katelyn K. Johnson, Joshua E. Rosen, Michelle C. Salazar, Daniel J. Boffa · 2016 · The Annals of Thoracic Surgery
  4. New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study
    Thomas Klikovits, Zoltán Lohinai, Katalin Fábián, Márton Gyulai, Mária Szilasi, Judit Varga, Erika Baranya, Orsolya Pipek, István Csabai, Zoltán Szállási et al. · 2018 · Lung Cancer
  5. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial
    Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter Ernst Huber, Laila König, Meinhard Kieser, Jürgen Debus et al. · 2019 · BMC Cancer
  6. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer
    Wouter Willem Mellema, Lucie Masen-Poos, Egbert Frederik Smit, Lizza E.L. Hendriks, Joachim G.J.V. Aerts, Ariën Termeer, Martijn Goosens, Hans J.M. Smit, Michel M. van den Heuvel, Anthonie J. van der Wekken et al. · 2015 · Lung Cancer
  7. Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
    Daniel Botelho Costa, Susan E. Jorge, Jason P. Moran, Jason A. Freed, Jessica Ann Zerillo, Mark S. Huberman, Susumu S. Kobayashi · 2016 · Journal of Thoracic Oncology
  8. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs
    Zhiyong Liang, Ying Cheng, Yuan Chen, Yanping Hu, Wei-Ping Liu, You Lü, Jie Wang, Ye Wang, Gang Wu, Jianming Ying et al. · 2017 · Cancer Letters
  9. Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non‐small cell lung cancer cells
    Justyna Kutkowska, Leon Strządała, Andrzej Rapak · 2017 · Cancer Science
  10. Juglanin inhibits lung cancer by regulation of apoptosis, ROS and autophagy induction
    Liang Chen, Yaqiong Xiong, Jing Xu, Jipeng Wang, Zili Meng, Yongqing Hong · 2017 · Oncotarget
  11. Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment
    Rashmi Koul, Shrinivas Rathod, Arbind Dubey, Bashir Bashir, Amitava Chowdhury · 2018 · Lung Cancer
  12. DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53
    Muli Wudu, Hongjiu Ren, Linping Hui, Jun Jiang, Siyang Zhang, Yitong Xu, Qiongzi Wang, Hongbo Su, Xizi Jiang, Runa Dao et al. · 2019 · Journal of Experimental & Clinical Cancer Research
  13. [18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non–Small Cell Lung Cancer
    Sarah A. Mattonen, Guido Davidzon, Shaimaa H. Bakr, Sebastian Echegaray, Ann N. C. Leung, Minal Vasanawala, George Horng, Sandy A. Napel, Viswam S. Nair · 2019 · Tomography
  14. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer
    Chia‐Lin Liu, Su-Feng Chen, Min-Zu Wu, Shu‐Wen Jao, Yaoh‐Shiang Lin, Chin‐Yuh Yang, Tsai‐Yu Lee, Lian-Wu Wen, Guo‐Lun Lan, Shin Nieh · 2016 · Oncotarget
  15. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer
    Jin Seon Im, Amanda Cernosek Herrmann, Chantale Bernatchez, Cara Haymaker, Jeffrey J. Molldrem, Waun Ki Hong, Roman Perez-Soler · 2016 · PLoS ONE
  16. Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer
    John Boyle, Bradley G. Ackerson, Lin Gu, Chris R. Kelsey · 2017 · Advances in Radiation Oncology
  17. Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial
    Anthony M. Brade, Frederik K. Wenz, Friederike L.A. Koppe, Yolande N. Lievens, Belén San Antonio, Neill Iscoe, Anwar Hossain, Nadia Chouaki, Suresh Senan · 2018 · International Journal of Radiation Oncology*Biology*Physics
  18. Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy
    Nikhil Yegya‐Raman, Wei Zou, Ke Nie, Jyoti Dhar Malhotra, Salma K. Jabbour · 2018 · Journal of Thoracic Disease
  19. FOXP3 activated-LINC01232 accelerates the stemness of non-small cell lung carcinoma by activating TGF-β signaling pathway and recruiting IGF2BP2 to stabilize TGFBR1
    Lihua Julie Zhu, Ying Liu, Haijuan Tang, Peng Wang · 2022 · Experimental Cell Research
  20. Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller
    Jung‐Jyh Hung, Yi‐Chen Yeh, Yu–Chung Wu, Teh‐Ying Chou, Wen‐Hu Hsu · 2017 · Journal of Thoracic Oncology
  21. Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.
    Erik E. Folch, Daniel Botelho Costa, JEFFREY P. WRIGHT, Paul A. VanderLaan · 2015 · PubMed Central
  22. Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
    You‐cai Zhu, Xing‐hui Liao, Wenxian Wang, C. Xu, Wu Zhuang, Lihua Zhong, Kaiqi Du, Yanping Chen, Gang Chen, Meiyu Fang · 2017 · OncoTargets and Therapy
  23. A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer
    Brian C. Gulack, Chi‐Fu Jeffrey Yang, Paul J. Speicher, Babatunde A. Yerokun, Betty Caroline Tong, Mark W. Onaitis, Thomas Anthony D’Amico, David H. Harpole, Matthew Galen Hartwig, Mark F. Berry · 2016 · The Annals of Thoracic Surgery
  24. Long noncoding RNA LINC00961 inhibits cell proliferation and induces cell apoptosis in human non–small cell lung cancer
    Zhiwen Huang, Wei Lei, Jin Tan, Haibo Hu · 2018 · Journal of Cellular Biochemistry
  25. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas
    Xiaohong Liang, Qing Li, Bin Xu, Song Hu, Qianyun Wang, Yan Li, Yun Zong, Sujuan Zhang, Chong Li · 2019 · International Journal of Clinical Oncology
  26. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer
    Iain Phillips, Sabrina Sandhu, Margreet Lüchtenborg, Susan Harden · 2019 · Clinical Oncology
  27. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma
    Jizhuang Luo, Rui Wang, Baohui Han, Jie Zhang, Heng Zhao, Wentao Fang, Qingquan Luo, Jun Yang, Yunhai Yang, Lei Zhu et al. · 2016 · Journal of Cancer Research and Clinical Oncology
  28. In vivo evidence that RBM5 is a tumour suppressor in the lung
    Duangporn Jamsai, D. Neil Watkins, Anne E. O’Connor, Donna Jo Merriner, Selen Gursoy, Anthony D. Bird, Beena Kumar, Alistair Miller, Timothy James Cole, Brendan John Jenkins et al. · 2017 · Scientific Reports
  29. The prognostic impact of lymph node metastasis in patients with non-small cell lung cancer and distant organ metastasis
    Jie Yang, Aimei Peng, Bo Wang, Aaron M. Gusdon, Xiaoting Sun, Gening Jiang, Peng Zhang · 2019 · Clinical & Experimental Metastasis
  30. Increased lysyl oxidase‐like 2 associates with a poor prognosis in non‐small cell lung cancer
    Ping Zhan, Xiao‐Jing Lv, Yanan Ji, Hai‐Yan Xie, Li Yu · 2016 · The Clinical Respiratory Journal
  31. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC
    Jun Ma, Zhenxian Zhao, Kaiming Wu, Zhe Xu, Kuanzhi Liu · 2016 · Gene
  32. A polysaccharide from Hedyotis diffusa interrupts metastatic potential of lung adenocarcinoma A549 cells by inhibiting EMT via EGFR/Akt/ERK signaling pathways
    Liyao Lin, Keluo Cheng, Zhan He, Qiongyan Lin, Yidong Huang, Chun‐Yuan Chen, Zhanqiang Xie, Lin Chen, Zhu Liang · 2019 · International Journal of Biological Macromolecules
  33. The possibility of clinical sequencing in the management of cancer
    Tadayuki Kou, Masashi Kanai, Shigemi Matsumoto, Yasushi Okuno, Manabu Muto · 2016 · Japanese Journal of Clinical Oncology
  34. Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells
    Zhe Dai, Xuyu Gu, Shouyan Xiang, Dandan Gong, Changfeng Man, Yu Jing Fan · 2020 · Biomarker Research
  35. Ratio of Mediastinal Lymph Node SUV to Primary Tumor SUV in 18F-FDG PET/CT for Nodal Staging in Non-Small-Cell Lung Cancer
    Jaehyuk Cho, Jae Gol Choe, Kisoo Pahk, Sunju Choi, Hye Ryeong Kwon, Jae Seon Eo, Hyo Jung Seo, Chulhan Kim, Sungeun Kim · 2016 · Nuclear Medicine and Molecular Imaging
  36. Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl)methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy
    Min Zhao, Yunhua Zheng, Qiyuan Zhao, Wei Zheng, Jianhong Yang, Heying Pei, Ling Liu, Kongjun Liu, Linlin Xue, Dexin Deng et al. · 2020 · European Journal of Medicinal Chemistry
  37. Somatic DNA mutation analysis in targeted therapy of solid tumours.
    Bing Yu, Sandra A O'Toole, Ronald J. Trent · 2015 · PubMed Central
  38. HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells
    Zhihao Wang, Pengchao Hu, Fang Tang, Conghua Xie · 2016 · Medical Oncology
  39. Radiation Therapy for Oligometastatic Non–Small Cell Lung Cancer
    Chad G. Rusthoven, Norman Yeh, Laurie E. Gaspar · 2015 · The Cancer Journal
  40. Next-generation sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology
    David M. DiBardino, David W. Rawson, Anjali Saqi, Jonas J. Heymann, Carlos A. Pagan, William A. Bulman · 2017 · CytoJournal
  41. Quality and Value of Subspecialty Reinterpretation of Thoracic CT Scans of Patients Referred to a Tertiary Cancer Center
    Brett W. Carter, Jeremy J. Erasmus, Mylene T. Truong, Jo-Anne O. Shepard, Wayne Lewis Hofstetter, Ryan Kristopher Clarke, Reginald F. Munden, Joseph Rodgers Steele · 2017 · Journal of the American College of Radiology
  42. Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma.
    Jiali Xu, Yongqian Shu, Tongpeng Xu, Wei Zhu, Tianzhu Qiu, Jun Li, Meiling Zhang, Jing Xu, Renhua Guo, Kaihua Lu et al. · 2018 · PubMed Central
  43. Management of Lung Cancer Presenting with Solitary Bone Metastasis
    Claudiu Nistor, Adrian Ciuche, Anca-Pati Cucu, Cornelia Niţipir, Cristina Orlov Slavu, Bogdan Şerban, Adrian Cursaru, Bogdan Stefan Cretu, Cătălin Cîrstoiu · 2022 · Medicina
  44. Treatment of Unfit Patients With Advanced Non–Small-Cell Lung Cancer: Definition Criteria According an Expert Panel
    Filippo de Marinis, Emilio Bria, Paul Baas, Marcello Tiseo, Andrea Camerini, Adolfo Gino Favaretto, Cesare Gridelli · 2015 · Clinical Lung Cancer
  45. The role of endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes
    Ye Gu, Hong Shi, Chunxia Su, Xiaoxia Chen, Shijia Zhang, Wěi Li, Fengying Wu, Guanghui Gao, Hao Wang, Haiqing Chu et al. · 2017 · Oncotarget
  46. BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
    Xuanzong Li, Shijiang Wang, Butuo Li, Zhen Wang, Shuheng Shang, Yang Washington Shao, Xindong Sun, Linlin Wang · 2018 · Targeted Oncology
  47. MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer
    Ke Li, Conghu Yuan · 2020 · International Journal of Molecular Medicine · Retracted
  48. Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
    Daniele Marinelli, Marco Siringo, Giulio Metro, Biagio Ricciuti, Alain Jonathan Gelibter · 2022 · Drugs in Context
  49. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung
    Thomas Muley, Ying He, Vinzent Rolny, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc Andre Schneider, Michael A. Meister, Felix J.F. Herth et al. · 2019 · Lung Cancer
  50. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
    Tianhong Li, Patricia Mucci LoRusso, Michael L. Maitland, Sai‐Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey J. Yuen, Anthony W. Tolcher · 2016 · Journal of Hematology & Oncology
  51. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
    Jacques L. Cadranel, Keunchil Park, Oscar G. Arrieta, Miklos Pless, Edmond A. Bendaly, Dony Patel, Medha Sasané, A. Nosal, Elyse Swallow, Philip Galebach et al. · 2016 · Lung Cancer
  52. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy
    Matthew Koshy, Renuka Malik, Michael T. Spiotto, Usama X. Mahmood, Chad G. Rusthoven, David Jonathan Sher · 2017 · Lung Cancer
  53. Next-Generation Sequencing Approach to Non–Small Cell Lung Carcinoma Yields More Actionable Alterations
    Mitra Mehrad, Somak Roy, Humberto E. Trejo Bittar, Sanja Đačić · 2017 · Archives of Pathology & Laboratory Medicine
  54. Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma
    Tianxiang Chen, Jizhuang Luo, Haiyong Gu, Yu Gu, Qingyuan Huang, Yiyang Wang, Jiajie Zheng, Yunhai Yang, Haiquan Chen · 2017 · The Annals of Thoracic Surgery
  55. Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma
    Ravi Salgia · 2016 · Expert Review of Molecular Diagnostics
  56. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1
    Ruirui Cheng, Chunya Lu, Guojun Zhang, Guowei Zhang, Guoqiang Zhao · 2017 · Oncology Reports · Retracted
  57. Role of LINC00152 in non-small cell lung cancer
    Hong Yu, Shubin Li · 2020 · Journal of Zhejiang University SCIENCE B
  58. Factors predicting organ-specific distant metastasis in patients with completely resected lung adenocarcinoma
    Jung‐Jyh Hung, Wen‐Juei Jeng, Yu‐Chung Wu, Teh‐Ying Chou, Wen‐Hu Hsu · 2016 · Oncotarget
  59. From biportal to uniportal video-assisted thoracoscopic anatomical lung resection
    Jia-Ming Chang, Kam-Hong Kam, Yi‐Ting Yen, Wei-Li Huang, Wei Chen, Yau‐Lin Tseng, Ming‐Ho Wu, Wu‐Wei Lai, Diego González-Rivas · 2016 · Medicine
  60. CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer
    Tomohiko Sakabe, Junya Azumi, Tomohiro Haruki, Yoshihisa Umekita, Hiroshige Nakamura, Goshi Shiota · 2017 · Oncology Letters
  61. Relationship between computed tomography morphology and prognosis of patients with stage I non-small cell lung cancer
    Jun Ma, Yun-Long Yang, Ye Wang, Xuewei Zhang, Xuesong Gu, Zhenchang Wang · 2017 · OncoTargets and Therapy
  62. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)
    Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc Andre Schneider, Hendrik Dienemann, Michael A. Meister et al. · 2018 · Lung Cancer
  63. Evidence for Expanding Invasive Mediastinal Staging for Peripheral T1 Lung Tumors
    Emily A. DuComb, Benjamin A. Tonelli, Ya Tuo, Bernard F. Cole, Vitor Mori, Jason H. T. Bates, George R. Washko, Raúl San Jośe Estépar, C. Matthew Kinsey · 2020 · CHEST Journal
  64. Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it
    Maria Drizou, Elias Alexandros Kotteas, Nikolaos Konstantinos Syrigos · 2017 · Clinical & Translational Oncology
  65. Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
    Chang Gon Kim, Hyo Sup Shim, Min Hee Hong, Yoon Jin Cha, Su Jin Heo, Hyung Soon Park, Jee Hung Kim, Jin Gu Lee, Chang Young Lee, Byoung Chul Cho et al. · 2017 · Oncotarget
  66. Subsolid pulmonary nodules: Controversy and perspective
    Mark Morris Hammer, Hiroto Hatabu · 2020 · European Journal of Radiology Open
  67. Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter
    Shanshan Wu, Bangdong Liu, Youhong Zhang, Ruohui Hong, Shihua Liu, Tao Xiang, Tianyu Tao, Junchao Cai, Jueheng Wu, Mengfeng Li et al. · 2021 · Oncogene
  68. Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer
    Talha Shaikh, Thomas M. Churilla, Colin T. Murphy, Nicholas George Zaorsky, Alan D. Haber, Mark A. Hallman, Joshua E. Meyer · 2016 · Journal of Thoracic Oncology
  69. A decision tree model for predicting mediastinal lymph node metastasis in non-small cell lung cancer with F-18 FDG PET/CT
    Kyoungjune Pak, Keun-young Kim A, Mi‐Hyun Kim, Jung Seop Eom, Min Ki Lee, Jeong Su Cho, Yun Seong Kim, Bum‐Soo Kim, Seong‐Jang Kim, In Joo Kim · 2018 · PLoS ONE
  70. RFC3 induces epithelial‑mesenchymal transition in lung adenocarcinoma cells through the Wnt/β‑catenin pathway and possesses prognostic value in lung adenocarcinoma
    Shulei Gong, Xiaohan Qu, Shize Yang, Siyu Zhou, Peiwen Li, Qigang Zhang · 2019 · International Journal of Molecular Medicine
  71. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma
    Meghan Shea, Mark S. Huberman, Daniel Botelho Costa · 2016 · Journal of Thoracic Oncology
  72. Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma
    Jung‐Jyh Hung, Yi‐Chen Yeh, Wen‐Hu Hsu · 2018 · Thoracic Cancer
  73. Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries
    Stephanie G. C. Kroeze, Corinna Fritz, Lucas Basler, Eleni Gkika, Thomas Baptist Brunner, Anca‐Ligia Grosu, Matthias Gückenberger · 2019 · Strahlentherapie und Onkologie
  74. Prevalence and Predictors of Inappropriate Delivery of Palliative Thoracic Radiotherapy for Metastatic Lung Cancer
    Matthew Koshy, Renuka Malik, Usama X. Mahmood, Zain Ali Husain, Ralph R. Weichselbaum, David Jonathan Sher · 2015 · JNCI Journal of the National Cancer Institute
  75. Effects of combined general-epidural anesthesia and total intravenous anesthesia on cellular immunity and prognosis in patients with non-small cell lung cancer: A comparative study
    Qiang Xu, Nian-Jun Shi, Hao Zhang, Yanmei Zhu · 2017 · Molecular Medicine Reports
  76. Decreased IL‐27 Negatively Correlated with Th17 Cells in Non‐Small‐Cell Lung Cancer Patients
    Minchao Duan, Zhengqing Ning, Zhi-Jun Fu, Jianquan Zhang, Guangnan Liu, Qiu Wei, Xiaoyu Zheng · 2015 · Mediators of Inflammation
  77. Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy
    Richard S. Matulewicz, Jeffrey J. Tosoian, C.J. Stimson, Ashley Evan Ross, Meera Reddy Chappidi, Tamara Levin Lotan, Elizabeth B. Humphreys, Alan Wayne Partin, Edward Matthew Schaeffer · 2016 · The Journal of Urology
  78. Caspase 8polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy
    Di Liu, Wen Xu, Xi Ding, Yang Yang, Yanlin Lu, Ke Fei, Bo Su · 2017 · Cancer Biology & Therapy
  79. A novel hybrid of 3-benzyl coumarin seco-B-ring derivative and phenylsulfonylfuroxan induces apoptosis and autophagy in non-small-cell lung cancer
    Mengxue Dong, Tao Ye, Yongyan Bi, Qian Wang, Kudelaidi Kuerban, Jiyang Li, Meiqing Feng, Ke Wang, Ying Chen, Li Ye · 2018 · Phytomedicine
  80. Investigation of LINC00342 as a poor prognostic biomarker for human patients with non–small cell lung cancer
    Huaping Tang, Lei Zhao, Meng Li, Tingtian Li, Yueqin Hao · 2018 · Journal of Cellular Biochemistry
  81. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer
    Daniel M. Sheinson, William Bruce Wong, Ning Wu, Aaron Scott Mansfield · 2020 · Lung Cancer
  82. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials
    Zhiqiang Li, Hai-Cui Yan, Jingjing Gu, Yongliang Yang, Ming-Kui Zhang, Xinjian Fang · 2020 · Pharmacological Research
  83. Radiotherapy in Lung Cancer: Current and Future Role
    Esengül Koçak Üzel · 2019 · SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
  84. Protein regulator of cytokinesis-1 expression: prognostic value in lung squamous cell carcinoma patients
    Ping Zhan, Guangmin Xi, Hongbing Liu, Yafang Liu, Wujian Xu, Qingqing Zhu, Zejun Zhou, Yingying Miao, Xiaoxia Wang, Jiajia Jin et al. · 2017 · Journal of Thoracic Disease
  85. Lymph node metastasis in lung squamous cell carcinoma and identification of metastasis‐related genes based on the Cancer Genome Atlas
    Ming Dong, Hao Gong, Tong Li, Xin Li, Jinghao Liu, Hongbing Zhang, Minghui Liu, Gang Chen, Hongyu Liu, Jun Chen · 2019 · Cancer Medicine
  86. The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion
    Yoonki Hong, Sunmin Park, Myoung Kyu Lee · 2022 · Scientific Reports
  87. Surgical Management of Oligometastatic Non–Small Cell Lung Cancer
    Michael D. Lanuti · 2016 · Thoracic surgery clinics/Thorac. surg. clin.
  88. Utilization of lung cancer cell lines for the study of lung cancer stem cells (Review)
    Yuyi Wang, Ming Jiang, Chi Du, Yang Yu, Yanyang Liu, Mei Li, Feng Luo · 2018 · Oncology Letters
  89. Should minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system?
    Tianxiang Chen, Jizhuang Luo, Haiyong Gu, Yu Gu, Jia Huang, Qingquan Luo, Yunhai Yang · 2018 · Journal of Thoracic Disease
  90. The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer
    Udit Chaddha, D. Kyle Hogarth, Septimiu Dan Murgu · 2019 · Annals of Translational Medicine
  91. Babaodan inhibits cell growth by inducing autophagy through the PI3K/AKT/mTOR pathway and enhances antitumor effects of cisplatin in NSCLC cells.
    Qi Wang, Zhile Liu, Kunpeng Du, Min Liang, Xiongjie Zhu, Zhongjian Yu, Rui Chen, Lingyu Qin, Ying Li, Yanfang Zheng · 2019 · Europe PMC (PubMed Central)
  92. Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer
    Andréanne Gagné, Michèle Orain, Diana N. Ionescu, Ming‐Sound Tsao, David Joubert, Philippe Joubert · 2020 · Lung Cancer
  93. Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors
    Yan Liu, Galen F. Gao, John Dorrance Minna, Noelle Sevilir Williams, Kenneth D. Westover · 2021 · Lung Cancer
  94. Visceral pleural invasion predict a poor survival among lung adenocarcinoma patients with tumor size ≤ 3cm
    Tianxiang Chen, Jizhuang Luo, Rui Wang, Haiyong Gu, Yu Gu, Qingyuan Huang, Yiyang Wang, Jiajie Zheng, Chang Gu, Xufeng Pan et al. · 2017 · Oncotarget
  95. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status
    Dalong Wang, Minghui Zhang, Xuan Gao, Lijuan Yu · 2016 · PLoS ONE
  96. The number of resected lymph nodes is associated with the long-term survival outcome in patients with T2 N0 non-small cell lung cancer
    Yingsheng Wen, Kexing Xi, Ke-Xiang Xi, Ru-Si Zhang, Gong-Ming Wang, Zirui Huang, Lanjun Zhang · 2018 · Cancer Management and Research
  97. Management of Stage IIIA (N2) Non-Small Cell Lung Cancer: A Transatlantic Perspective
    Gaetano Rocco, Katie Sue Nason, Alessandro Brunelli, Gonzálo Varela, Thomas K. Waddell, David Randolph Jones · 2016 · The Annals of Thoracic Surgery
  98. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
    Tianhong Li, Bilal Piperdi, William V. Walsh, Mimi Kim, Laurel A. Beckett, Rasim A. Gucalp, Missak Haigentz, Venu Gopal Bathini, Huiyu Wen, Kaili Zhou et al. · 2016 · Clinical Lung Cancer
  99. Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
    Alexander Le, Saeed K Alzghari, Gary W. Jean, Ninh My La-Beck · 2017 · Therapeutics and Clinical Risk Management
  100. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy
    Hossein Borghaei, Yeun Mi Yim, Annie Guérin, Irina Pivneva, Sherry Shi, Mayank Gandhi, Raluca Ionescu‐Ittu · 2018 · Lung Cancer